DaVita Inc (NYSE: DVA) has a higher price-to-earnings ratio of 13.60x compared to its average ratio. DVA has 36-month beta value of 1.11. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for DVA is 71.82M, and currently, short sellers hold a 8.14% ratio of that float. The average trading volume of DVA on June 13, 2025 was 824.23K shares.
DVA) stock’s latest price update
DaVita Inc (NYSE: DVA)’s stock price has plunge by -0.59relation to previous closing price of 138.17. Nevertheless, the company has seen a -0.28% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-30 that DENVER, May 30, 2025 /PRNewswire/ — DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita.
DVA’s Market Performance
DaVita Inc (DVA) has experienced a -0.28% fall in stock performance for the past week, with a -4.60% drop in the past month, and a -2.67% drop in the past quarter. The volatility ratio for the week is 0.75%, and the volatility levels for the past 30 days are at 1.38% for DVA. The simple moving average for the last 20 days is -1.25% for DVA stock, with a simple moving average of -10.41% for the last 200 days.
Analysts’ Opinion of DVA
Many brokerage firms have already submitted their reports for DVA stocks, with Barclays repeating the rating for DVA by listing it as a “Equal Weight.” The predicted price for DVA in the upcoming period, according to Barclays is $133 based on the research report published on March 06, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see DVA reach a price target of $142, previously predicting the price at $100. The rating they have provided for DVA stocks is “Buy” according to the report published on August 07th, 2023.
Deutsche Bank gave a rating of “Hold” to DVA, setting the target price at $72 in the report published on November 01st of the previous year.
DVA Trading at -3.35% from the 50-Day Moving Average
After a stumble in the market that brought DVA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.52% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DVA starting from BERKSHIRE HATHAWAY INC, who sale 103,274 shares at the price of $139.45 back on May 27 ’25. After this action, BERKSHIRE HATHAWAY INC now owns 33,796,541 shares of DaVita Inc, valued at $14,401,483 using the latest closing price.
BERKSHIRE HATHAWAY INC, the 10% Owner of DaVita Inc, sale 64,066 shares at $137.81 during a trade that took place back on May 23 ’25, which means that BERKSHIRE HATHAWAY INC is holding 33,899,815 shares at $8,828,933 based on the most recent closing price.
Stock Fundamentals for DVA
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.32 for the gross margin
The net margin for DaVita Inc stands at 0.07. The total capital return value is set at 0.14. Equity return is now at value 260.92, with 4.98 for asset returns.
Based on DaVita Inc (DVA), the company’s capital structure generated 1.02 points at debt to capital in total, while cash flow to debt ratio is standing at 0.19. The debt to equity ratio resting at -46.13. The interest coverage ratio of the stock is 4.04.
Currently, EBITDA for the company is 2.72 billion with net debt to EBITDA at 4.46. When we switch over and look at the enterprise to sales, we see a ratio of 1.72. The receivables turnover for the company is 4.7for trailing twelve months and the total asset turnover is 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.25.
Conclusion
To put it simply, DaVita Inc (DVA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
